Products - Lung cancer | Topic

Showing 32 products

Date | Title

New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal) (TA1118)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 January 2026
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer (TA1108)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 November 2025
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor (TA1103)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 October 2025
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy (TA1099)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 October 2025
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 August 2025
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 January 2026
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
4 February 2026
Suspected Cancer: recognition and referral (update)
Status:
In development | In consultation
Programme:
NICE guideline
Consultation end date:
2 February 2026
Expected publication date:
25 March 2026
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
8 April 2026
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
21 May 2026
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
30 September 2026
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
2 December 2026
Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
14 April 2027
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tarlatamamb for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with oleclumab or monalizumab for treating unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6626]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [TSID12280]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Lung cancer Products

Filter

Product type

Guidance programme

Status

New and updated
1 selected

Showing 32 products

Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal) (TA1118)

Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer (TA1108)

Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor (TA1103)

Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy (TA1099)

Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)

Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]

Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]

Suspected Cancer: recognition and referral (update)

Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]

Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]

Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]

Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]

Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]

Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]

Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]

Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]

Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]

Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]

Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472]

Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]

Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]

Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]

Tarlatamamb for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]

Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]

Durvalumab with oleclumab or monalizumab for treating unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6626]

Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]

Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [TSID12280]

Lung cancer Products

Filter

Product type

Guidance programme

Status

New and updated1 selected

Showing 32 products

New and updated
1 selected